Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma WW, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ. Weekes CD, et al. Clin Cancer Res. 2013 Mar 1;19(5):1232-43. doi: 10.1158/1078-0432.CCR-12-3529. Epub 2013 Feb 22. Clin Cancer Res. 2013. PMID: 23434733 Clinical Trial.
Portal Vein or Superior Mesenteric Vein Thrombosis with Dose-Escalated Radiation for Borderline or Locally Advanced Pancreatic Cancer.
Smart AC, Niemierko A, Wo JY, Ferrone CR, Tanabe KK, Lillemoe KD, Clark JW, Blaszkowsky LS, Allen JN, Weekes C, Ryan DP, Warshaw AL, Castillo CF, Hong TS, Keane FK. Smart AC, et al. J Gastrointest Surg. 2023 Nov;27(11):2464-2473. doi: 10.1007/s11605-023-05796-5. Epub 2023 Aug 14. J Gastrointest Surg. 2023. PMID: 37578568
Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis.
Fong ZV, Verdugo FL, Fernandez-Del Castillo C, Ferrone CR, Allen JN, Blaszkowsky LS, Clark JW, Parikh AR, Ryan DP, Weekes CD, Hong TS, Wo JY, Lillemoe KD, Qadan M. Fong ZV, et al. Among authors: weekes cd. J Am Coll Surg. 2023 Jun 1;236(6):1126-1136. doi: 10.1097/XCS.0000000000000499. Epub 2022 Dec 8. J Am Coll Surg. 2023. PMID: 36729817
Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma.
Qiao G, Fong ZV, Bolm L, Fernandez Del-Castillo C, Ferrone CR, Servin-Rojas M, Pathak P, Lau-Min K, Allen JN, Blaszkowsky LS, Clark JW, Parikh AR, Ryan DP, Weekes CD, Roberts HM, Wo JY, Hong TS, Lillemoe KD, Qadan M. Qiao G, et al. Among authors: weekes cd. Ann Surg. 2024 Jul 1;280(1):118-125. doi: 10.1097/SLA.0000000000006131. Epub 2023 Oct 13. Ann Surg. 2024. PMID: 37830225
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA. Weekes CD, et al. Invest New Drugs. 2011 Oct;29(5):1057-65. doi: 10.1007/s10637-010-9413-7. Epub 2010 Mar 23. Invest New Drugs. 2011. PMID: 20306339 Free PMC article. Clinical Trial.
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. Ma WW, et al. Among authors: weekes cd. Clin Cancer Res. 2012 Apr 1;18(7):2048-55. doi: 10.1158/1078-0432.CCR-11-2813. Epub 2012 Feb 14. Clin Cancer Res. 2012. PMID: 22338014 Clinical Trial.
Patient-derived tumour xenografts as models for oncology drug development.
Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Tentler JJ, et al. Among authors: weekes cd. Nat Rev Clin Oncol. 2012 Apr 17;9(6):338-50. doi: 10.1038/nrclinonc.2012.61. Nat Rev Clin Oncol. 2012. PMID: 22508028 Free PMC article. Review.
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors.
Xin Y, Li J, Wu J, Kinard R, Weekes CD, Patnaik A, Lorusso P, Brachmann R, Tong RK, Yan Y, Watts R, Bai S, Hegde PS. Xin Y, et al. Among authors: weekes cd. Clin Cancer Res. 2012 Nov 1;18(21):6040-8. doi: 10.1158/1078-0432.CCR-12-1652. Epub 2012 Sep 7. Clin Cancer Res. 2012. PMID: 22962439 Clinical Trial.
Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.
Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD. Bradshaw-Pierce EL, et al. Among authors: weekes cd. PLoS One. 2013;8(3):e58089. doi: 10.1371/journal.pone.0058089. Epub 2013 Mar 8. PLoS One. 2013. PMID: 23520486 Free PMC article.
87 results